Lilly's New Obesity and Diabetes Drugs Outperform Competitors in Clinical Trials
TL;DR Summary
Eli Lilly's new oral GLP-1 receptor agonist, orforglipron, demonstrated superior efficacy in reducing A1C levels and weight loss compared to oral semaglutide in a 52-week Phase 3 trial involving adults with type 2 diabetes, with promising safety and tolerability profiles.
- Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial Eli Lilly and Company
- Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial CNBC
- Daily weight loss pill can help cut body weight by a fifth, trial shows The Guardian
- Lilly’s Obesity Pill Will Have Far-Reaching Effect, Doctors Say Bloomberg.com
- Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
9 min
vs 10 min read
Condensed
98%
1,936 → 40 words
Want the full story? Read the original article
Read on Eli Lilly and Company